Kanabo Group PLC UK Moves to License e-cigarettes and vaporizers
06 Diciembre 2021 - 1:00AM
RNS Non-Regulatory
TIDMKNB
Kanabo Group PLC
06 December 2021
Kanabo Group Plc
("Kanabo" or the "Company")
UK Moves to License e-cigarettes and vaporizers
Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D
Company that focuses on the distribution of cannabis-derived
products for medical patients and wellness CBD consumers, welcomes
news that the UK could be the first country in the World to
prescribe medicinally licensed e-cigarettes and Vaporizers
New UK Guidelines
The U.K government agency, Medicines and Healthcare Products
Regulatory Agency ("MHRA") has announced that the UK's National
Health Service ("NHS") could soon prescribe e-cigarettes to help
patients stop smoking tobacco products.
To achieve a licence, products would need to meet the standards
of quality, safety, and efficacy expected of medicinal products. If
successful, this would potentially allow safe and effective
products to be made available for prescription, for tobacco smokers
who wish to quit or reduce smoking.
The updated guidance provides further details on the steps
required to license an e-cigarette as a medicinal product and has
invited e-cigarette manufacturers to submit products to undergo the
same approval process as prescribed medicines. This could make the
UK the first country to prescribe medicinally licensed
e-cigarettes.
If a product receives MHRA approval, clinicians could then
decide on a case-by-case basis whether it would be appropriate to
prescribe an e-cigarette to NHS patients to help them quit
smoking.
Dr June Raine, Chief Executive of the MHRA, said: " The evidence
is clear that e-cigarettes are less harmful to health than smoking
tobacco and that nicotine-containing e-cigarettes can help people
quit smoking for good. The updated guidance on licensing
requirements we have published today is a strong first step towards
availability of safe and effective licensed e-cigarette
products.
The MHRA will continue to support companies in the development
of safe and effective e-cigarette products, to encourage the
licensing of e-cigarette products as medicines in order to support
patient-centred care and access."
The UK's Health and Social Care Secretary Sajid Javid said:
"This country continues to be a global leader on healthcare,
whether it's our COVID-19 vaccine roll-out saving lives or our
innovative public health measures reducing people's risk of serious
illness.
Opening the door to a licensed e-cigarette prescribed on the NHS
has the potential to tackle the stark disparities in smoking rates
across the country, helping people stop smoking wherever they live
and whatever their background."
Avihu Tamir, CEO of Kanabo Group said, "Any research that helps
patients has to be welcomed. Kanabo started its commercial life by
addressing the issue of developing a device to deliver a reliable
and repeatable metered dose of medicinal cannabis to help patients
combat their ailments. The Company's proprietary VapePod is now a
class-leading medical device available in the UK. As the UK's
regulatory framework outlines a higher entry barrier for the
industry, the global vaping industry will witness a more
standardised and concentrated market where industry leaders, such
as Kanabo, will further strengthen their leading positions.
Meanwhile, the whole industry, the supply chain and patients will
benefit from such a well-regulated and standardised market in
turn."
For further information, please visit
http://www.kanabogroup.com/ or contact the following:
Kanabo Group Plc
Avihu Tamir, CEO Via Vox Markets
Peterhouse Capital Ltd
Eran Zucker (Financial Adviser) Tel: +44 (0)20 7469 0930
Lucy Williams / Charles Goodfellow (Corporate Broker) Tel: +44 (0)20 7469 0930
Vox Markets (Investor Relations)
Kat Perez KanaboGroup@voxmarkets.co.uk
About Kanabo Group Plc
Kanabo Group Plc is an R&D company currently selling a range
of wellness CBD Products in the Primary Markets and Medical
Cannabis Products. The company's core strategy is to increase
revenues from the sale of its Retail CBD Products in the wellness
sector and to grow the Kanabo brand through its marketing
initiatives.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFSSFAIEFSELE
(END) Dow Jones Newswires
December 06, 2021 02:00 ET (07:00 GMT)
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024